Monthly Archives: March 2022

BioCardia Announces New Center for Medicare and Medicaid Services Reimbursement Code Applicable to the CardiAMP Cell Therapy Procedure – GuruFocus.com

Posted: March 25, 2022 at 2:10 am

SUNNYVALE, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. [ BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, announces the designation of a new reimbursement code for the CardiAMP Cell Therapy procedure to transplant autologous bone marrow cells to treat heart failure from the U.S. Center for Medicare and Medicaid Services (CMS).

This new CMS code to be submitted by hospitals performing the CardiAMP cell therapy procedure is available April 1, 2022. The code provides clear reimbursement for the study procedure performed for both the treatment and control arms for the ongoing cell therapy pivotal trials in two cardiovascular indications: the CardiAMP Cell Therapy Heart Failure Trial (NCT02438306) and the CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial (NCT03455725).

This most recent action by CMS further represents its commitment to improving the way ischemic heart failure is treated and is supportive of BioCardias therapeutic investigational product candidates furnished by a comprehensive approach to bone marrow cell harvest, processing, and delivery in a single procedure, commented Peter Altman, Ph.D., BioCardias CEO. Further, it provides additional clarity of CMS financial support for institutions conducting the CardiAMP Cell Therapy Heart Failure Trial and CardiAMP Chronic Myocardial Ischemia Trials. We are grateful for our ongoing collaboration with both CMS and the FDA as we continue to demonstrate the promise of our technology.

The new reimbursement code (designated C9782) is for a blinded procedure for New York Heart Association (NYHA) class ii or iii heart failure, or Canadian Cardiovascular Society (CCS) class iii or iv chronic refractory angina; transcatheter intramyocardial transplantation of autologous bone marrow cells or placebo control, autologous bone marrow harvesting and preparation for transplantation, left heart catheterization including ventriculography, all laboratory service and all imaging with or without guidance, performed in approved investigational device exemption (IDE) study.

Patients interested in learning about the CardiAMP Cell Therapy Trials can visit http://www.cardiamp.com or http://www.clinicaltrials.gov for more information.

About the CardiAMP Cell Therapy ProgramCardiAMP Cell Therapy uses a patients own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure to potentially stimulate the bodys natural healing response. The CardiAMP Cell Therapy Heart Failure Trial is the first multicenter clinical trial of an autologous cell therapy to prospectively screen for cell therapeutic potency in order to improve patient outcomes. CardiAMP Cell Therapy incorporates three proprietary elements not previously utilized in investigational cardiac cell therapy, which the company believes improves the probability of success of the treatment: a pre-procedural diagnostic for patient selection, a high target dosage of cells, and a proprietary delivery system that has been shown to be safer than other intramyocardial delivery systems and more successful for enhancing cell retention. CAUTION - Limited by United States law to investigational use.

About BioCardiaBioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP autologous and NK1R+ allogeneic cell therapies are the Companys biotherapeutic product candidates in clinical development. The Company's current products include the Helix transendocardial delivery system, the Morph steerable guide and sheath catheter portfolio and the AVANCE steerable introducer family. BioCardia also partners with other biotherapeutic companies to provide its Helix systems and development support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction. The CardiAMP Cell Therapy Heart Failure Trial has been supported financially by the Maryland Stem Cell Research Fund and the Center for Medicare and Medicaid Services. For more information visit: http://www.BioCardia.com.

Forward Looking Statements:This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations. These forward-looking statements include, without limitation, statements relating to study enrollment expectations and the likelihood of safety and patient benefit, and ultimate success of our clinical cell therapy programs.

We may use terms such as believes, estimates, anticipates, expects, plans, intends, may, could, might, will, should, approximately or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardias Form 10-K filed with the Securities and Exchange Commission on March 30, 2021, under the caption titled Risk Factors. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

INVESTOR CONTACT:David McClung, Chief Financial Officer[emailprotected](650) 226-0120

MEDIA CONTACT:Anne Laluc, MarketingEmail: [emailprotected] Phone: 650-226-0120

Read more from the original source:
BioCardia Announces New Center for Medicare and Medicaid Services Reimbursement Code Applicable to the CardiAMP Cell Therapy Procedure - GuruFocus.com

Posted in Stem Cell Therapy | Comments Off on BioCardia Announces New Center for Medicare and Medicaid Services Reimbursement Code Applicable to the CardiAMP Cell Therapy Procedure – GuruFocus.com

Adjunct Treatment With Uproleselan Could Enhance Effects of Chemotherapy in AML – OncLive

Posted: March 25, 2022 at 2:10 am

The novel E-selectin antagonist uproleselan could augment the use of chemotherapy in patients with acute myeloid leukemia (AML) without increasing toxicity and potentially lessening some of the adverse effects associated with chemotherapy, according to David Sallman, MD.

Unlike some traditional combination therapies in oncology, where 2 or more agents target different aspects of a cancer, uproleselan can amplify the effects of chemotherapy by allowing the treatment to attack cancer cells that would normally go unaffected, Sallman added.

I would consider [uproleselan] more of an adjunct [treatment because] it is helping [the chemotherapy] target these cells that are not targetable, traditionally, by chemotherapy [alone] and allowing the chemotherapy to exert its normal function, Sallman said. Without uproleselan, this would likely not be possible.

In an interview with OncLive, Sallman, assistant member, Department of Malignant Hematology, Moffitt Cancer Center, provided perspective on the novel agent uproleselan, its efficacy in a phase 1/2 trial (NCT02306291), and its investigation in phase 3 trials in AML.

Sallman: To give a little bit of context, in general for AML, remissions can be achieved with both intensive and non-intensive therapies in sometimes up to 70% or greater of patients. However, relapse is a major issue, with a vast majority of patients relapsing unless they are bridged to allogeneic stem cell transplant. [There is always the concern] of having some leftover amount of disease after frontline therapy, which is associated with poor outcomes, even in those groups of patients that are ultimately bridged to transplant. Improving the depth of remission and targeting leukemic stem cells that may be left behind is of paramount importance to further improve treatment outcomes.

Uproleselan is a novel and specific E-selectin inhibitor. As a brief background, [E-selectin] is a vascular-adhesion molecule that is expressed on the vascular endothelium that helps leukocytes stick to the vessel wall. The thought is it helps keep these leukemic stem cells protected almost in a little house. A lot of times, these cells will not be dividing. Intensive chemotherapy does not target the cells that are not dividing, because it requires active cell cycle for that to occur.

There are other potential bone-marrow microenvironment markers that may be targeted, but this is the one that is furthest along. There is other important work that shows that E-selectin may help support and nurture these leukemic stem cells.

Ultimately, the goal is [determining whether] E-selectin [can] be used in conjunction with intensive chemotherapy to target these specific leukemic stem cells that are a major driver of relapse. One question with that is: Are the cells that are minimal residual disease [MRD] positive or left behind leukemic stem cells? Those comparisons and novel translational analyses, particularly on the single-cell level, [have yet to be done]. Essentially, the goal [is determining whether we can] target leukemic stem cells and help eradicate them in conjunction with more of our standard-of-care therapies.

The long-term goal is [to] improve the cure rates and overall survival [OS] for patients with AML. For a high percentage of this group, which has been predominantly targeting either relapsed/refractory leukemia or frontline patients that are over the age of 60 years, transplant is also part of that. [We are] also thinking of the long-term improvement of outcomes and prevention of relapse after transplant.

The goal is to improve the depth of remission and the duration of survival in patients that may not be able to go to transplant, but particularly in the setting of transplant, to improve the depth of remission to allow for the best long-term survival in patients that ultimately go to transplant.

[It is] a very specific inhibitor, so there should not be any increase in toxicity. It is specifically targeting E-selectin or CD62E and does not have any other significant off-target [effects]. It is very selective, and an interesting observation [from the phase 1/2 trial is that fewer instances of] mucositis, which is 1 of the most important toxicities of standard intensive chemotherapy, were seen [with the addition of uproleselan, and that may be a benefit. The hope is that we are not going to add any toxicity. If anything, we may have less toxicity [with the combination of uproleselan and chemotherapy].

By blocking E-selectin, uproleselan prevents this protective bone-marrow niche or microenvironment from protecting the cells from survival and eventually resistance to chemotherapy. By directly abrogating this E-selectin interaction of the bone-marrow microenvironment to the leukemic stem cell, it loses its protective house that should make it more susceptible to intensive chemotherapy.

I do not find it as much of a synergistic combination. It is not [like] a lot of clinical trials where when you use 2 [agents] together there is more, for example, apoptosis, cell-cycle arrest, [and] cytol effects against the leukemic cell.

The clinical trial of uproleselan first focused on patients with relapsed/refractory leukemia, and the chemotherapy backbone they used in this was MEC [mitoxantrone/etoposide/cytarabine]. Essentially, the investigators first did a phase 1 dose escalation, and the recommended phase 2 dose [RP2D] ultimately was found to be 10 mg/kg. They then did a phase 2 expansion of this combination with the RP2D of uproleselan in patients with relapsed/refractory AML. An important caveat is that most of these patients had failed just 1 line of therapy. Patients who fail more than 1 line of therapy are even less likely to have good outcomes and represent a distinct cohort when you are comparing them with other relapsed/refractory groups.

In a smaller cohort of 25 newly diagnosed patients over the age of 60 years, uproleselan [was combined] with standard 7+3 [chemotherapy] with idarubicin and cytarabine.

There are other salvage chemotherapy regimens such as FLAG [fludarabine/cytarabine/ granulocyte colony stimulating factor (G-CSF)], CLAG [cladribine/cytarabine/G-CSF], or CLAG-M [cladribine/cytarabine/G-CSF/mitoxantrone]. In retrospective studies, there has been overall no difference [between these regimens], but potentially, MEC has had slightly lower response rates. Additionally, in patients over the age of 60 years, cytarabine and daunorubicin [Vyxeos] is approved as frontline treatment and was superior to standard 7+3 intensive chemotherapy independent of age. Although the phase 1/2 trial focused on this similar group of patients, they were [required] to either have myelodysplastic-related changes, therapy-related history, or an antecedent myeloid neoplasm.

When we look at overall outcomes [with the addition of uproleselan to chemotherapy], the response rates are good. A composite complete remission [CR] was achieved in 41% of patients in the relapsed/refractory group, with a median OS of 8.8 months. In the frontline group, the composite CR rate was up to 72%, with a median OS of 12.6 months.

[It is worth noting the phase 1/2 trials were] single-arm studies. The response rates are good. The big challenge is figuring out whether [the response rates would be] any different [with] the absence of uproleselan. The problem in cross-trial comparisons is there are retrospective cohorts that have similar response rates and there are some that [have] worse [response rates]. The response rates appear to be at least as good and I would say on the favorable side of [treatment with chemotherapy alone.] Survival was not dramatically different in these cohorts of patients, particularly in the setting of additional salvage therapies that we have, such as targeted inhibitors and hypomethylating agent [HMA]/venetoclax [Venclexta]based combinations. The safety profile [of uproleselan] looked good. The critical next steps will be phase 3 clinical trials.

[Uproleselan] is a very selective inhibitor of E-selectin, and we do not expect a lot of increased toxicity [with the agent]. [It was] noteworthy that no dose-limiting toxicities were observed [in the phase 1 study]. Overall, likely from a combination of pharmacokinetic and pharmacodynamic data, the 10 mg/kg dose was utilized, [with] no significant increase, [and] if anything, a lower rate of mucositis, which can be a significant toxicity.

Clearly, [uproleselan] is safe. It does not add toxicity in combination with intensive chemotherapy. For example, [no] prolonged cytopenias were seen, which is often a major challenge when we are looking at novel combinations with intensive therapeutic options.

The good thing is uproleselan does not seem to add significant toxicities [to chemotherapy]. There can always be some infusional adverse [effects (AEs)], but for severe or life-threatening toxicities, which is really the focus when we are thinking about intensive chemotherapy, there is no increase [in toxicity with uproleselan]. Overall, the 60-day mortality rates were comparable. They are not dramatically lower, but are potentially on the low side in patients who are over the age of 60 years.

We have learned that non-randomized studies, particularly in this group of patients, are somewhat irrelevant in thinking [about] the long-term benefit of these medications, so conducting randomized trials is important. The data in Blood [on the phase 1/2 trial] clearly support the randomized phase 3 trials.

There are 2 main phase 3 trials ongoing right now: [NCT03701308 and NCT03616470]. Both are placebo-controlled studies, and they are mirrored after [the phase 1/2 study]. One is being done in the first-line setting in patients over the age of 60 [years and is evaluating] 7+3 chemotherapy with or without uproleselan and the other is being done in the salvage setting. In this case, the investigators are allowing 2 options: MEC or FLAG-IDA [fludarabine/cytarabine/idarubicin/G-CSF]. FLAG-IDA and CLAG-M are more commonly utilized regimens in the first-line salvage setting.

Those trials are both ongoing with a long-term primary end point of OS. Patients who are over the age of 60 years cannot have FLT3 mutations. They also cannot have an antecedent myeloid neoplasm or therapy-related disease. This is partially in the context that cytarabine and daunorubicin has an approval. There will be a little bit of overlap [between patient populations in the 2 trials]. For example, [treatment for] AML with myelodysplastic-related changes without those antecedent histories could be improved [with the addition of uproleselan]. Again, there are reasonable comparator arms and a clear primary end point to see whether the addition of uproleselan does improve outcomes either in the frontline setting or in the relapsed/refractory setting for first-line salvage therapy.

If these trials are positive, they would support [uproleselans] approval either in a frontline or relapsed/refractory space. What is nice about uproleselan is that its toxicity profile is good.

[It is important to note] that the landscape of frontline AML is changing quite quickly. For elderly [patients with AML who are] not fit for intensive chemotherapy, so classically over the age of 75 years or younger with specific comorbidities, HMAs in combination with venetoclax are a standard of care. Although, already at some academic centers, places are already favoring an HMA plus venetoclax over intensive chemotherapy in this group of patients who are 60 years of age or older. The question is: Are we going to move away from intensive chemotherapy? Does this [regimen] make [intensive chemotherapy] potentially less relevant? If the combination of an HMA and venetoclax becomes a standard for all patients over the age of 60 years, you could say response rates are comparable and MRD negativity rates are at least as good [compared with intensive chemotherapy]. We do not have the long-term data or data after allogeneic stem cell transplant [ASCT], which is a big [gap] in those datasets, but clearly some have already started to transition to [using an HMA plus venetoclax in that population].

There are prospective clinical trials comparing standard chemotherapy regimens in this age group with azacitidine and venetoclax. There is a clinical trial, not registrational, looking at uproleselan with an HMA plus venetoclax. We will eventually have some safety and outcome data there. [Would uproleselan have the same relevance] if we had an approved agent and the standard of care shifted? That is a critical question in the changing paradigm for [identifying] the best treatment.

Hopefully there will be some translational data. Are there subsets of patients that may have the greatest benefit with uproleselan? Could this therapy be used in conjunction with novel cellular therapy, which is a major focus, particularly in the relapsed/refractory space? There are 2 key trials with the goal of getting this agent approved. How it will eventually be utilized may change over time based on the results, but [we are] eagerly awaiting the data readout of these studies.

[It will be intriguing to see] additional translational data. Hopefully there will be robust single-cell analyses looking at leukemic stem cells. Can we really see, particularly in the placebo-controlled trial, the eradication of those? That will speak a lot to the mechanism of action of [uproleselan]. [Our improved technologies will help us understand] what happens preclinically vs in clinical trial patients. Therefore, I hope those key analyses will be done, and hopefully we will also [identify whether] there are subsets that may have the greatest benefit of therapy and may help us understand which patients to utilize that approach in, assuming the [trials] are positive.

Read the rest here:
Adjunct Treatment With Uproleselan Could Enhance Effects of Chemotherapy in AML - OncLive

Posted in Stem Cell Therapy | Comments Off on Adjunct Treatment With Uproleselan Could Enhance Effects of Chemotherapy in AML – OncLive

TCR-Depleted Haploidentical Grafts Are a Safe Alternative to HLA-Matched Unrelated Donor Stem Cell Transplants for Infants with Severe Combined…

Posted: March 25, 2022 at 2:10 am

Hematopoietic stem cell transplantation and gene therapy are the only curative therapies for severe combined immunodeficiency (SCID). In patients lacking a matched donor, TCR/CD19-depleted haploidentical family donor transplant (TCR-HaploSCT) is a promising strategy. Conditioned transplant in SCID correlates to better myeloid chimerism and reduced immunoglobulin dependency. We studied transplant outcome in SCID infants according to donor type, specifically TCR-HaploSCT, and conditioning, through retrospective cohort analysis of 52 consecutive infants with SCID transplanted between 2013 and 2020. Median age at transplant was 5.1months (range, 0.816.6). Donors were TCR-HaploSCT (n=16, 31.4%), matched family donor (MFD,n=15, 29.4%), matched unrelated donor (MUD,n=9, 17.6%), and matched unrelated cord blood (CB,n=11, 21.6%). Forty-one (80%) received fludarabine/treosulfan-based conditioning, 3 (6%) had alemtuzumab only, and 7 (14%) received unconditioned infusions. For conditioned transplants (n=41), 3-year overall survival was 91% (95% confidence interval, 5299%) for TCR-HaploSCT, 80% (4198%) for MFD, 87% (3698%) for MUD, and 89% (4398%) for CB (p=0.89). Cumulative incidence of grade IIIV acute graft-versus-host disease was 11% (279%) after TCR-HaploSCT, 0 after MFD, 29% (7100%) after MUD, and 11% (279%) after CB (p=0.10). 9/10 patients who received alemtuzumab-only or unconditioned transplants survived. Myeloid chimerism was higher following conditioning (median 47%, range 0100%) versus unconditioned transplant (median 3%, 09%) (p<0.001), as was the proportion of immunoglobulin-free long-term survivors (n=29/36, 81% vsn=4/9, 54%) (p<0.001). TCR-HaploSCT has comparable outcome to MUD and is a promising alternative donor strategy for infants with SCID lacking MFD. This study confirms that conditioned transplant offers better myeloid chimerism and immunoglobulin freedom in long-term survivors.

Excerpt from:
TCR-Depleted Haploidentical Grafts Are a Safe Alternative to HLA-Matched Unrelated Donor Stem Cell Transplants for Infants with Severe Combined...

Posted in Stem Cell Therapy | Comments Off on TCR-Depleted Haploidentical Grafts Are a Safe Alternative to HLA-Matched Unrelated Donor Stem Cell Transplants for Infants with Severe Combined…

Boundaries in stem cell and reformative medicine research – EurekAlert

Posted: March 25, 2022 at 2:09 am

Frontiers in Stem Cell and Regenerative Medicine Research informs on multidisciplinary areas relevant to stem cell research and their application in regenerative medicine. The series is vital reading for researchers seeking updates in stem cell therapeutics and regenerative medicine.

The tenth volume of Frontiers in Stem Cell and Regenerative Medicine Researchpresents important recent developments in this fast-growing field.

Volume 10 includes 5 chapters on these topics:

-Novel drugs and their stem cell-based targets forosteoporosis: challenges and proceedings

-The role ofcancer stem cellsin disease progression and therapy resistance

-Stem cells fromhuman exfoliated deciduous teethin tissue regeneration

-The fate oftoxicological studies: from animal models to stem cell-based methods

-Effect of material properties on differentiation ofmesenchymal stem cells

Audience: Pharmaceutical scientists, biomedical researchers, stem cell biologists, pre-clinical and clinical researchers, life science, researchers, and healthcare professionals in regenerative medicine

About the Editors:

Prof. Atta-ur-Rahman, Ph.D. in Organic Chemistry from Cambridge University (1968) has 1,232 international publications (45 international patents and 341 books). He received the following awards: Fellow Royal Society (FRS) London (2006), UNESCO Science Prize (1999), Honorary Life Fellow Kings College, Cambridge University (2007), Academician (Foreign Member) Chinese Academy of Sciences (2015), Highest Civil Award for Foreigners of China (Friendship Award, 2014), High Civil Award Austria ("Grosse Goldene Ehrenzeischen am Bande") (2007), Foreign Fellow Chinese Chemical Society (2013), Sc.D. Cambridge University (UK) (1 987), TWAS (Italy) Prize (2009). He was the President of Network of Academies of Sciences of Islamic Countries (NASIC), Vice President TWAS (Italy), Foreign Fellow Korean Academy of Science & Technology, President Pakistan Academy of Sciences (2003-2006) and (2011 2014). He was the Federal Minister for Science and Technology of Pakistan (2000 2002), Federal Minister of Education (2002) and Chairman Higher Education Commission/ Federal Minister (2002-2008), Coordinator General of COMSTECH (OIC Ministerial Committee) (1996-2012), and the Editor-in-Chief of Current Medicinal Chemistry.

Dr. Shazia Anium is the Professor of the Chemistry Department and the Director of Cholistan Institute of Desert Studies, the Islamic University of Bahawalpur, Pakistan. She is experienced medicinal and natural product chemist. She has authored and co-authored more than 116 research papers (Impact Factor: 208) and a US patent. She has edited 09 books and has published 03 chapters in international books. She has accomplished the synthesis of several naturally occurring aminoglycosides that can be used as antibiotics. Dozen of students have completed their MS degrees under her supervision and couple of others are pursing for their MS/PhD degrees. As recognition of her contributions to science, she has been awarded with 03 International awards like Fellowship from Islamic World Academy of Sciences, Postdoctoral fellowship from Ministry of Culture and Education, Spain and a Young Chemist Award from Third World Academy of Sciences, Italy. She also has several national awards on her credit.

Keywords

Osteoporosis, cancer stem cells, therapy resistance, human exfoliated deciduous teeth in tissue regeneration, animal models, differentiation of mesenchymal stem cells.

Please visit the link for more information: https://bit.ly/3hzRENV

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Read this article:
Boundaries in stem cell and reformative medicine research - EurekAlert

Posted in Regenerative Medicine | Comments Off on Boundaries in stem cell and reformative medicine research – EurekAlert

Orthopedic Regenerative Medicine Market Analysis 2022, Size, Share, Trend and Growth in Future Scope 2022-2028 | Baxter International, Anika…

Posted: March 25, 2022 at 2:09 am

The Regenerative Medicine (Bone and Joint) Market research provides a clear understanding of the markets major geographies, and also the key segments and sub-segments. The study focuses on the state of regional development, including sales volume, cost, and growth volume. The report also gives detailed company descriptions of leading players in the Regenerative Medicine (Bone and Joint) industry that are included in Regenerative Medicine (Bone and Joint) Market. The research investigates all of the segments based on various parameters such as market dominance, volume, and CAGR. On the fact that it is based, revenue, and sales in the Regenerative Medicine (Bone and Joint) market, the analysts have also thoroughly examined different regions such as North America, Europe, and the Asia Pacific. For this report on the Regenerative Medicine (Bone and Joint) market, the researchers employed extensive mixed research approaches and technologies.

The analysts have segmented the global market based on raw material, type, application, sales, and region. The study also analyzes the present landscape of the ever-evolving business sector and the present and future of the market. It covers important insights pertaining to established companies operating in the global Regenerative Medicine (Bone and Joint) market. The report provides in-depth information by market segment to help you monitor performance and make important decisions for growth and profitability. The report also proposes significant data regarding marketing channel development trends and market position.

Leading players of Regenerative Medicine (Bone and Joint) Market including

Anika Therapeutics, Inc, Arthrex, Inc., Baxter International, Inc., CONMED Corporation, Johnson & Johnson, Medtronic, Plc, Smith & Nephew plc, Stryker Corporation, Zimmer Holdings, Inc., Aziyo Biologics, and Ortho Regenerative Technologies Inc.

Get PDF Research Report Brochure @https://www.coherentmarketinsights.com/insight/request-pdf/3566

Main Region Coverage: Production, Demand, and Forecasts by Country:

North America (USA, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and other European countries)

Asia Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and other South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, South Africa, and other the Middle East and Africa)

Key Questions Answers in Regenerative Medicine (Bone and Joint) Market Report:

Which Manufacturing Morden Development Technology prefer for Regenerative Medicine (Bone and Joint)?

Who Are the current Key Players in This Regenerative Medicine (Bone and Joint) Industry with Their (Company Profile, Product Information, and Contact Information)?

What is the current as well as future market status of Regenerative Medicine (Bone and Joint)?

Who are the key stakeholders in the market?

What Are Industry Dynamics, Challenges, and Opportunities of Regenerative Medicine (Bone and Joint) Market?

What Is Economic Impact on Regenerative Medicine (Bone and Joint) Industry?

What Was the worldwide Market Status of Regenerative Medicine (Bone and Joint) Market with Capacity, Production Value, Cost, and profit?

Buy This Complete Business Report With Flat USD 2000 Off @https://www.coherentmarketinsights.com/promo/buynow/3566

In the end, The Regenerative Medicine (Bone and Joint) Market Trend for Advancement is examined, along with marketing channels. Finally, the viability of new capital investments is evaluated, and research findings are presented. The Regenerative Medicine (Bone and Joint) Market Report also includes information on market share and production growth for each product in the Regenerative Medicine (Bone and Joint) market.

Contact:

Coherent Market Insights1001 4th Ave, #3200 Seattle, WA 98154, U.S.Email:[emailprotected]United States of America: +1-206-701-6702United Kingdom: +44-020-8133-4027Japan: +050-5539-1737India: +91-848-285-0837

The rest is here:
Orthopedic Regenerative Medicine Market Analysis 2022, Size, Share, Trend and Growth in Future Scope 2022-2028 | Baxter International, Anika...

Posted in Regenerative Medicine | Comments Off on Orthopedic Regenerative Medicine Market Analysis 2022, Size, Share, Trend and Growth in Future Scope 2022-2028 | Baxter International, Anika…

Cell Expansion Market To Reach Value Of USD 39.74 Billion By 2027 | Increase In The Adoption Of Regenerative Medicine Drives The Growth Of Market,…

Posted: March 25, 2022 at 2:09 am

VANCOUVER, BC, March 22, 2022 /PRNewswire/ -- The global cell expansion market is estimated to reach value of USD 39.74 Billion by 2027, according to a current analysis by Emergen Research. Cell expansion is witnessing a surge in demand owing to an increase in automated solutions. Automation in the production of gene therapies and cell therapies products reduces the cost of production and decreases workforce.

Emergen_Research_Logo

The emergence of cell-based therapy is expected to further growth of cell expansion market. Advancement in tissue engineering and regenerative medicine have provided growth opportunity for cell expansion market. Demand for regenerative medicine is growing rapidly to develop clinical therapies for repair, maintenance, replacement, and enhancement of biological function. Cell expansion is an important part of regenerative medicine as it provides a better understanding of neurodegenerative diseases. Thus, increase in the adoption of regenerative medicine drives the growth of cell expansion market.

Get Free Sample PDF Copy of the Report @ https://www.emergenresearch.com/request-sample/952

Lack of skilled professionals and high cost of the operations are expected to restrain growth of cell expansion market. Risk of contamination during the cell expansion procedure is also expected to hinder its adoption by the consumers.

Key Highlights of Report

In June 2019, Demcon acquired a share in Scinus Cell Expansion Company. Scinus is involved in developing equipment for stem cell therapy. The company is working on a technology that is cheaper, more reproducible, and less labor-intensive than the existing technology.

The instruments segment is forecast to register a faster rate during the forecast period owing to automation in bioreactors. Emergence of automation enables the tracking of processes and allows for effective time usage of skilled professionals.

Growing genetic disorders are driving the demand for embryonic stem cells. Research is being undertaken to use embryonic stem cells for eradication of genetic diseases. An increase in chronic diseases all across the globe is fueling the revenue growth of the segment.

Increase in incidence of cancer has propelled the research by biopharmaceutical companies in cell-based research. There are several funds allocated by public and private companies for cancer and cell-based research.

The market in Asia Pacific is expected to register the fastest rate owing to the increasing amount of research activities in developing nations. Several companies in the region are investing in developing advanced therapeutic tools, which is encouraging the adoption of cell expansion technology in the region.

Key companies include Danaher Corporation, Thermo Fisher Scientific, Inc., Corning Incorporated, Lonza, Merck KGAA, Terumo Corporation, Stemcell Technologies, Inc., Cellexus, Becton, Dickinson and Company, and Himedia Laboratories.

Story continues

Discount Available on Cell Expansion market report @ https://www.emergenresearch.com/request-discount/952

For the purpose of this report, Emergen Research has segmented global cell expansion market based on product, cell type, application, end-user, and region:

Product Outlook (Revenue, USD Million; 20172027)

Cell Type Outlook (Revenue, USD Million; 20172027)

Explore Complete Report Description and Table of Contents of Cell Expansion Market Report@ https://www.emergenresearch.com/industry-report/cell-expansion-market

Application Outlook (Revenue, USD Million; 20172027)

End-User Outlook (Revenue, USD Million; 20172027)

Regional Outlook (Revenue, USD Million; 20172027)

Get Customized Report as Per Your Specific Requirement@ https://www.emergenresearch.com/request-for-customization/952

Have a Look at Related Research Insights:

Medical Grade Tubing Market Size, Share, Trends, By Material (Polyvinyl Chloride, Polyolefin, Thermoplastic elastomer and thermoplastic polyurethane, Silicone), By Application (Bulk Disposable Tubing), By Structure and By Region Forecast to 2030

3D Organ Printing Market, By Material (Living Cells, Hydrogels, Extracellular Matrices, Other Biomaterials), By Printing Component (Inkjet Printing, Extrusion Printing, Laser-Assisted Printing), By End-use, and By Region Forecast to 2030

Pilates and Yoga Studios Market Size, Share, Trends, By Type (Yoga Classes, Pilates Classes, Pilates & Yoga Accreditation Training), By Application, By Enterprise Size, By Sales Channel, and By Region Forecast to 2030

Immunocytokines Market Size, Share, Trends, By Disease Indication (Tumor and Cancer, Rheumatoid Arthritis), By Targeting Site (Liver, Hypothalamus, Fat Muscle, B and T Lymphocytes, Bone Marrow Endothelium), and By Region Forecast to 2028

Bioreactors Market, By Material Type (Glass, Single-Use, Stainless Steel), By Range (5L-20L, 20L-200L, 200L-1500L, Above 1500L), By Control Type (Manual, Automated), By Suppliers, By Production Scale, By End-Use, and By Region Forecast to 2030

Cryotherapy Market By Product (Localized Cryotherapy Devices, Cryosurgery Devices, Cryochambers & Cryosaunas, Gas Cylinders, Others), By Therapy (Icepack Therapy, Cryosurgery, Chamber Therapy), By Application, By End-Use, and By Region Forecast to 2028

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trend's existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

Eric Lee Corporate Sales SpecialistEmergen Research | Web: http://www.emergenresearch.com Direct Line: +1 (604) 757-9756 E-mail: sales@emergenresearch.com Visit for More Insights: https://www.emergenresearch.com/insights Explore Our Custom Intelligence services | Growth Consulting Services Read our Press Release on Cell Expansion @ https://www.emergenresearch.com/press-release/global-cell-expansion-market

Cision

View original content:https://www.prnewswire.com/news-releases/cell-expansion-market-to-reach-value-of-usd-39-74-billion-by-2027--increase-in-the-adoption-of-regenerative-medicine-drives-the-growth-of-market-says-emergen-research-301507831.html

SOURCE Emergen Research

Link:
Cell Expansion Market To Reach Value Of USD 39.74 Billion By 2027 | Increase In The Adoption Of Regenerative Medicine Drives The Growth Of Market,...

Posted in Regenerative Medicine | Comments Off on Cell Expansion Market To Reach Value Of USD 39.74 Billion By 2027 | Increase In The Adoption Of Regenerative Medicine Drives The Growth Of Market,…

Cryopreservation Equipment Market revenue to cross USD 11255.02 million by 2028 says, The Insight Partners – Digital Journal

Posted: March 25, 2022 at 2:09 am

According to The Insight Partners new market research study on Cryopreservation Equipment Market Forecast to 2028 COVID-19 Impact and Global Analysis by Type, Cryogen Type, Application, and End User, the market is expected to reach US$ 11,255.02 million by 2028 from US$ 5,798.82 million in 2021; it is estimated to grow at a CAGR of 9.9% from 2021 to 2028.

Cryopreservation plays an important part in the field of regenerative medicine as it facilitates stable and secure storage of cells and other related components for a prolonged time. Regenerative medicine enables replacing diseased or damaged cells, tissues, and organs by retrieving their normal function through stem cell therapy. Owing to the advancements in the medical technology, stem cell therapy is now being considered as an alternative to traditional drug therapies in the treatment of a wide range of chronic diseases, including diabetes and neurodegenerative diseases. Moreover, the US Food and Drug Administration (FDA) has approved blood-forming stem cells. The blood-forming stem cells are also known as hematopoietic progenitor cells that are derived from umbilical cord blood. The growing approvals for stem cell and gene therapies are eventually leading to the high demand for cryopreservation equipment.

Download sample PDF Copy of Cryopreservation Equipment Market study at: https://www.theinsightpartners.com/sample/TIPRE00023243/

Prominent players operating in the cryopreservation equipment market include Thermo Fisher Scientific Inc., Gold Sim Cellular Science LLC, Brooks Automation, Inc, Avantor, Inc., Hamilton Company, PHC Holdings Corporation, General Electric Company, Cryoport Systems, LLC., Antech Group Inc., Cryofab, BioLife Solutions, and ZhongkeMeiling Cryogenics Company Limited.

Market players are launching new and innovative products and services to maintain their position in the cryopreservation equipment market. In May 2021, Stirling Ultracold has been acquired by BioLife Solutions, Inc for cell and gene therapies and the broader biopharma market. In return for all of Stirlings outstanding shares, BioLife issued 6,646,870 shares of ordinary stock.

The COVID-19 pandemic has had a mixed impact on the cryopreservation equipment market. Restricted access to family planning services as well as diverted focus of people due to economic uncertainties and recession, and disturbed work-life balance have led to rise in egg and embryo freezing activities at fertility clinics during the pandemic. As a result, the rising use of cryopreservation equipment is boosting the market growth. Furthermore, supply chain disruption caused due to congestion of ports and disturbances in other transport means has substantially affected the distribution of cryopreservation equipment and other accessories.

Inquiry for Discount on Cryopreservation Equipment Market at: https://www.theinsightpartners.com/discount/TIPRE00023243/

Based on type, the cryopreservation equipment market is segmented into freezers, sample preparation systems, and accessories. In 2020, the freezers segment held the largest share of the market, and it is expected to register the highest CAGR during 20212028. In ultracold freezers, liquid nitrogen is used for the successful preservation of more complex biological structures by virtually seizing all biological activities.

Following are a few instances of stem cell and gene therapies approved by the FDA and other regulatory bodies.

In February 2021, Bristol Myers Squibb (Juno Therapeutics, Inc.) received an FDA approval for Breyanzi, a CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy. The CAR-T cell therapy is used for treating relapsed or refractory large B-cell lymphoma in adults.In March 2021, Novartis AG received approval from the Health Sciences Authority of Singapore for the commercialization of the first CAR-T therapy named Kymriah, which is claimed as a one-time treatment procedure run individually for each patient. The therapy was approved under the new cell, tissue, and gene therapy products (CTGTP) regulatory framework.In July 2020, Kite, a Gilead Company, received an approval from the US FDA for its Tecartus (formerly known as KTE-X19) CAR-T cell therapy. The therapy is designed for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).In May 2019, Vericel Corporation received an approval for its MACI (autologous cultured chondrocytes on porcine collagen membrane).In December 2017, Spark Therapeutics received an approval from the US FDA for Luxturna. It is a one-time gene therapy product for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy.

Interested in Purchasing Cryopreservation Equipment Market Report? Click here @ https://www.theinsightpartners.com/buy/TIPRE00023243/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense, Food & beverage, Chemical and Materials, Semiconductors etc.

Contact Us:

Call: +1-646-491-9876

Email: [emailprotected]

View post:
Cryopreservation Equipment Market revenue to cross USD 11255.02 million by 2028 says, The Insight Partners - Digital Journal

Posted in Regenerative Medicine | Comments Off on Cryopreservation Equipment Market revenue to cross USD 11255.02 million by 2028 says, The Insight Partners – Digital Journal

AVITA Medical Announces Modification of BARDA Contract to Advance Development of RECELL System in Soft Tissue Reconstruction – Yahoo Finance

Posted: March 25, 2022 at 2:09 am

AVITA Medical

Funds will support completion of the ongoing pivotal clinical trial

VALENCIA, Calif. and MELBOURNE, Australia, March 21, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that the Biomedical Advanced Research and Development Authority (BARDA) has modified its existing contract with the Company to support AVITA Medicals clinical trial in soft tissue reconstruction. BARDA is a part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS).

We are extremely pleased that BARDA is supporting advanced treatment options for soft tissue reconstruction, said Dr. Mike Perry, Chief Executive Officer of AVITA Medical. The RECELL System has already proven itself as a safe and effective tool for those with burns, and we are committed to expanding its use to include all acute wounds. We are pleased BARDA recognizes the potential it holds for a broader group of patients experiencing trauma. BARDA has been an outstanding partner, and we are excited to continue our work to expand the indication for the RECELL System with their support.

Soft tissue reconstruction is of particular concern to BARDA and AVITA Medical, as skin grafting, the current standard of care for soft tissue reconstruction, requires the harvesting of donor skin which can result in an additional wound to the patient. Significant pain, delayed healing, risk of infection, the need for multiple procedures, discoloration and scarring are associated with donor site wounds. While skin grafting is commonly associated with burn treatment, in 2017, approximately 80% of acute wounds that required skin grafting were non-burn related injuries accounting for more than 200,000 procedures in the U.S.i

Story continues

AVITA Medical is currently completing a pivotal trial for the use of the RECELL System for soft tissue reconstruction. Currently, the RECELL System is indicated in the U.S. for treatment of acute thermal burns. The clinical trial will compare the clinical performance of conventional autografting to that of widely meshed autografting with the RECELL System on acute non-burn full-thickness skin defects, with the goal of demonstrating that less donor skin is needed without compromising healing outcomes. Topline data from the trial will be shared later this year.

AVITA Medical has had a long-term positive relationship with BARDA since September 2015 and was of fundamental importance to the Company being able to achieve premarket approval for the RECELL System in late 2018.

This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201500028C

ABOUT AVITA MEDICAL, INC.AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medicals patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patients own skin. The medical devices work by preparing a RES REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patients skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Medicals first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018 and a new ease-of-use design was approved in 2022. The RECELL System is indicated for use in the treatment of acute thermal burns. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patients own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 10,000 patients globally reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings, and precautions.

In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds, and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe. To learn more, visit http://www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as anticipate, expect, intend, could, may, will, believe, estimate, look forward, forecast, goal, target, project, continue, outlook, guidance, future, other words of similar meaning and the use of future dates. Forward-looking statements in this press release include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the companys control. Investors should not place considerable reliance on the forward-looking statements contained in this press release. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

This press release was authorized by the review committee of AVITA Medical, Inc.

FOR FURTHER INFORMATION:

i 2017 Procedural Data. 2019 DR/Decision Resources, LLC

View original post here:
AVITA Medical Announces Modification of BARDA Contract to Advance Development of RECELL System in Soft Tissue Reconstruction - Yahoo Finance

Posted in Regenerative Medicine | Comments Off on AVITA Medical Announces Modification of BARDA Contract to Advance Development of RECELL System in Soft Tissue Reconstruction – Yahoo Finance

Cell Therapy Market is Expected to Grow by USD 20.2 Billion Progressing at a CAGR of 14.5% By Forecast 2027 – Digital Journal

Posted: March 25, 2022 at 2:09 am

TheGlobal Cell Therapy Marketwas worth USD7.8 billion in 2021, according to a new analysis released by Maximize Market Research, and is expected to rise to USD 20.2 billion by 2027, with a CAGR of 14.5% percent over the forecast period. From the markets perspective, its ever-changing trends, industrial environment, existing market features, and the current short-term and long-term influence on the market

the research will aid decision-makers in developing the outline and strategies for organisations by region.

The implantation of a human cell to replace or repair damaged tissue or cells is known as cellular therapy. Therapy typically consists of live cells that are safely injected, implanted, or grafted into the patients body to have a therapeutic effect. T-cell and stem cell treatment are two types of cell therapy that are used to combat cancer via cell mediated immunity or to repair damaged tissues. For patients with long-term ailments, cell therapy has become a popular treatment option.

Cell Therapy Market Scope and Dynamics:

The Maximize Market Research report contains a detailed study of factors that will drive and restrain the growth of the Cell Therapy Market Globally. Significant advances in cell therapy, a growing emphasis on regenerative medicine, increased R&D activities in the life sciences sector to develop advanced cellular therapies, and the rising prevalence of cancer, musculoskeletal disorders, cardiovascular diseases, autoimmune disorders, and neurological diseases are all driving the global cell therapy market revenue growth.

Other significant factors driving global market revenue growth include increased awareness and commercialization of stem cell therapies, an increase in the number of clinical trials of new cell therapies, an increase in the use of human cells in cell therapy research and development, and an increase in cellular therapy manufacturing under Good Manufacturing Practices (GMP) supervision. Increased government investments in the healthcare industry, as well as increased collaborations between pharmaceutical and biotechnology behemoths and leading research institutes for the development of advanced cellular therapies for cancer, cardiovascular disease, and other severe chronic diseases, are expected to boost global cell therapy market revenue growth in the coming years.

The Impact of COVID-19 on the Cell Therapy Market:

The COVID-19 pandemic has impacted the majority of biopharmaceutical companies, but several cellular treatment development companies have seen a significant negative impact, which can be related to logistical issues as well as the manufacturing models used in this field. Furthermore, large and reliable funding is required to ensure successful commercial translation of cell-based medicines, a factor that was negatively impacted in 2020, affecting market growth even more.

Request For Free Sample @https://www.maximizemarketresearch.com/request-sample/126471

Cell Therapy Market Region Insights:

Regional analysis is another highly comprehensive part of the research and analysis study of the global Cell Therapy Market presented in the report. The global cell treatment market is dominated by North America. In 2020, North America held a total market share of 14.5%percent, as new institutions and institutes invest in R&D to propel cell therapy forward. Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Harvard Stem Cell Institute, and Yale Steam Cell Center are among the main universities in the United States that are involved in new research in cell regenerative technologies. During the forecasted period, Asia Pacific is expected to increase at a significant rate of 14.5%percent. China, South Korea, and Japan are spending extensively in regenerative medicine and stem cell therapies. Certain government-funded institutes are devoted to R&D with the goal of pushing the market forward.

What does the report include?

The study on the Global Cell Therapy Market includes qualitative characteristics such as drivers, constraints, and opportunities.The research looks at the current and future rivals in the Global Cell Therapy Market, as well as their product development strategies.The study examines the market in both qualitative and quantitative terms, and it is separated into three segments: component, deployment type, organisation size, and industry. Furthermore, the report provides comparable statistics for the key regions.For each of the above-mentioned segments, actual market sizes and predictions have been presented.

Cell Therapy Market Segmentation:

Global Cell Therapy Market, by Therapy Type:

AutologousAllogeneic

Global Cell Therapy Market, by Cell Type:

T-CellStem Cell

Global Cell Therapy Market, by Application:

MalignanciesMusculoskeletal DisorderAutoimmune DisorderDermatologyOthers

Global Cell Therapy Market, by End User:

Hospitals and clinicsAcademics and Research Institutes

By Region:

North AmericaEuropeAsia PacificSouth AmericaMiddle East and Africa

Key Players in Cell Therapy Market:

Kolon TissueGene Inc.Anterogen Co. Ltd.JCR Pharmaceuticals Co., Ltd.Castle Creek Biosciences, Inc.The Future of Biotechnology, MEDIPOSTOsiris Therapeutics, Inc.PHARMICELL Co., LtdTameika Cell Technologies, Inc.Cells for CellsNuVasive, Inc.Vericel CorporationCelgene CorporationThermo Fisher Scientific Inc.Merck KGaADanaher CorporationBecton, Dickinson, and CompanyLonza GroupSartorius AGTerumo BCTFresenius Medical Care AG & Co. KGaA

To Get a Detailed Report Summary and Research Scope of Cell Therapy MarketClick here @https://www.maximizemarketresearch.com/market-report/cell-therapy-market/126471/

About Maximize Market Research:

Maximize Market Research, a global market study firm with a dedicated team of specialists and data, has conducted thorough research on the Cell Therapy Market. Maximize Market Research is well-positioned to assess and predict market size while also taking into account the competitive landscape of the various industries. Maximize Market Research has a strong unified team of industry professionals and analysts across sectors to guarantee that the whole industry ecosystem, as well as current developments, new trends, and futuristic the technology effect of uniquely particular industries is taken into consideration.

Contact Maximize Market Research:

3rd Floor, Navale IT Park, Phase 2

Pune Banglore Highway, Narhe,

Pune, Maharashtra 411041, India

[emailprotected]

Go here to see the original:
Cell Therapy Market is Expected to Grow by USD 20.2 Billion Progressing at a CAGR of 14.5% By Forecast 2027 - Digital Journal

Posted in Regenerative Medicine | Comments Off on Cell Therapy Market is Expected to Grow by USD 20.2 Billion Progressing at a CAGR of 14.5% By Forecast 2027 – Digital Journal

Global Viral Vectors and Plasmid DNA Manufacturing Market is anticipated to reach US$2,381.5 Million in 2031: Visiongain Research Inc – Yahoo Finance

Posted: March 25, 2022 at 2:09 am

Visiongain Ltd

Visiongain has published a new report on Viral Vectors and Plasmid DNA Manufacturing Market 2021-2031. Forecasts by Vector Type (Adenovirus, Retrovirus, Plasmid DNA, AAV, Lentivirus, Others), Application (Antisense & RNAi, Gene Therapy, Cell Therapy, Vaccinology), Disease (Oncology, Genetic Disorders, Infectious Diseases, Others), End-Use (Pharma and Biopharma Companies, Research Institutes), Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa), PLUS COVID-19 Recovery Scenarios

Global viral vectors and plasmid DNA manufacturing market size is estimated to be valued at US$420.7million in 2020 and is anticipated to reach US$2,381.5 million in 2031 while growing at a CAGR of17.4% during the forecast period from 2021 to 2031.

Download Exclusive Sample of Report @ https://www.visiongain.com/report/viral-vectors-manufacturing-market-2021/#download_sampe_div

COVID-19 Impact on the Viral Vectors and Plasmid DNA Manufacturing Market

Due to increases in the therapies in progress, the dosages provided, & the patient populations targeted, viral vector production capacity has become increasingly reduced in recent years. The condition is aggravated by COVID-19. The number of companies developing innovative medicines such as cell, gene, & tissue-based therapies surpassed 1,000 in the first half of 2020, according to the ARM (Alliance for Regenerative Medicine). Since 2015, that represents an upsurge of almost 50%. Increases in clinical trial activity have corresponded to the emergence of successful advanced therapy companies.

Market Drivers

A Robust Pipeline for Gene Therapy and Viral Vectors

Almost 400 Embryonic cell and gene therapies address a broad variety of diseases. The overlapping areas of biomedical science with common therapeutic targets that target DNA or RNA within or outside the body are cell and gene therapy. To optimize functioning or tackle the disease, all techniques aim to alter genetic material. Specifically, gene therapy uses genetic material, or DNA, to cure an inherited or acquired disorder by modifying a patient's cells. The injection or transplantation of whole cells into a recipient for the treatment of an inherited or acquired disorder is cell therapy.

Story continues

Get Detailed TOC @ https://www.visiongain.com/report/viral-vectors-manufacturing-market-2021/#download_sampe_div

Increasing Capacities by Manufacturers Owing to Rising Demand

There is a growing need for realistic production methods for viral vectors that can be quickly standardized and scaled since cell and gene therapies have the ability to progress rapidly from clinical trials through commercialization. Brammer Bio and Pall Biotech are both designing and applying state-of-the-art solutions designed to speed up process growth and scale-up for the manufacture of viral vectors through ongoing efforts. While biological drug substances with lower molecular weight are often generated through fermentation, larger recombinant proteins, and monoclonal antibodies (mAbs) are usually manufactured using well-established platform processes, accounting for the largest fraction of biologics on the market today. Consequently, manufacturing equipment has been built for the production ofmAbs, and this room is well serviced by suppliers of equipment.

Market Opportunities

The rise in the Development of Allogeneic and Autologous Cell Therapy

The more commercially appealing development of allogeneic cell therapy currently dominates over the production of autologous cell therapy, while clinical research in support of patient-specific therapy is convincing. There are opportunities for both autologous and allogeneic cell therapies to be developed, which differ greatly in their production requirements, patient administration paths, and cost structures.

In an autologous transplant, the patient's own stem cells are used for transplantation purposes for the treatment of many diseases such as cancer. The stem cells are obtained from either bone marrow or blood and are then frozen for harvest purposes. High doses of chemo or radiation therapy damage different cells of the body. Thus, after these therapies during cancer treatment, the thawed stem cells are reintroduced into the patient's body to restore the damaged cells. As the patient's own cells are used during autologous stem cell transplantation, there would be no risk of transplant rejection. This type of transplant is mainly utilized for the treatment of types of leukemia, lymphomas, and multiple myeloma. It is occasionally used to treat cancers in children and follicular lymphoma.

Competitive Landscape

Some of the major companies operating in the global Viral Vectors and Plasmid DNA Manufacturing market are Merck KGaA, Lonza, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Cobra Biologics Ltd., Brammer Bio, Waisman Biomanufacturing, Genezen, YPOSKESI, Advanced BioScience Laboratories, Inc. (ABL, Inc.), Novasep Holding S.A.S, ATVIO Biotech Ltd, Vigene Biosciences, Inc., Cytiva, CEVEC Pharmaceuticals GmbH, Batavia Biosciences B.V, Biovian Oy, Wuxi AppTec Co., Ltd., VGXI, Inc., Paragon Bioservices, Inc., MiltenyiBiotec GmbH, SIRION Biotech GmbH, Virovek Incorporation, BioNTech IMFS GmbH, VIVEbiotech S.L., Creative Biogene, Vibalogics GmbH, Cell and Gene Therapy Catapult, BlueBird Bio, Addgene, Inc., Aldevron, L.L.C., Audentes Therapeutics, and BioMarin Pharmaceutical.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

To access the data contained in this document please email contactus@visiongain.com

Information found nowhere elseWith this new and exclusive report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your investment, research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Viral Vectors and Plasmid DNA Manufacturing market and leading companies. You will get the most recent data, opportunities, trends, and predictions.

Find more Visiongain research reports on Pharma Biotechnology Sector click on the following links:

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: catherine.walker@visiongain.com

About Visiongain

Visiongain is one of the fastest growing and most innovative, independent, market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports mean that you can have a bespoke piece of market intelligence customized to your very own business needs.

Contact:

Catherine WalkerPR at Visiongain Inc.Tel: + 44 0207 336 6100USA Tel: + 1 718 682 4567EU Tel: + 353 1 695 0006Toll Free: 00-1-646-396-5129Email: catherine.walker@visiongain.comWeb: https://www.visiongain.comFollow Us: LinkedIn | Twitter

-

SOURCE Visiongain Limited.

Visit link:
Global Viral Vectors and Plasmid DNA Manufacturing Market is anticipated to reach US$2,381.5 Million in 2031: Visiongain Research Inc - Yahoo Finance

Posted in Regenerative Medicine | Comments Off on Global Viral Vectors and Plasmid DNA Manufacturing Market is anticipated to reach US$2,381.5 Million in 2031: Visiongain Research Inc – Yahoo Finance